news
NICE recommends Novartis’ heart failure drug, Entresto
21 March 2016 | By Victoria White
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ heart failure drug, Entresto (sacubitrial/valsartan).
List view / Grid view
National Institute for Health and Care Excellence (NICE)
news
NICE says ‘no’ to talimogene laherparepvec in melanoma
16 March 2016 | By Victoria White
NICE says there is not enough evidence to be able to say whether talimogene laherparepvec is as effective as other drugs used to treat advanced melanoma...
news
NICE calls for more research into Alexion’s sebelipase alfa
18 February 2016 | By Victoria White
NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency...
news
Heart UK questions absence of lipidologists after NICE limits cholesterol-busting drug use
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
news
NICE says ‘no’ to alirocumab in draft guidance
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
news
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
NICE says ‘yes’ to Opdivo (nivolumab) in melanoma
22 January 2016 | By Victoria White
NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma...
news
NICE publishes new guideline to better tackle TB
13 January 2016 | By Victoria White
The new guidance combines clinical advice and public health guidance for the first time...
news
NICE says ‘yes’ to Santen’s dry eye disease treatment, ciclosporin
16 December 2015 | By Victoria White
Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)...
news
NICE says ‘yes’ to heart failure drug sacubitril valsartan
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
news
NICE recommends enzalutamide; consults on abiraterone
11 December 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has published draft guidance on two prostate cancer treatments - enzalutamide and abiraterone...
news
NICE says ‘no’ to asfotase alfa in draft guidance
3 December 2015 | By Victoria White
NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia...
news
NICE draft guidance recommends elosulfase alfa for MPS IVa
23 November 2015 | By Victoria White
The positive draft guidance follows the development of a managed access scheme by BioMarin and NHS England...
news
Cancer Drugs Fund public consultation launched
19 November 2015 | By Victoria White
The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing...
